The Korean Association for the Study of the Liver, founded in 1995 based on the “Korean Society for the Study of Liver” established in 1981, has grown into an exemplary association that serves as a role model for other national associations, thanks to the efforts and dedication of all our members. Since its inception, the Korean Association for the Study of the Liver has gained international recognition in the research and treatment of liver diseases, reaching an Impact Factor of 8.9 in 2019 for its official academic journal, Clinical and Molecular Hepatology (CMH), listed in SCIE.

During my tenure as the 16th Chairman, my focus will be on reevaluating and enhancing the efficiency of the established activities and operations of the Korean Association for the Study of the Liver rather than initiating many new projects.

First, I aim to elevate the international standing of the Korean Association for the Study of the Liver and CMH. While CMH has grown into an outstanding journal with an IF of 8.9, I aspire to push it beyond, making CMH a journal with an Impact Factor exceeding 15 points, establishing it as the leading medical journal in Korea and ranking within the top 10 among 93 gastroenterology journals. Additionally, efforts will be made to enhance international exchanges with other associations, fostering programs like Korea-Japan-Taiwan joint symposiums and KASL-AASLD joint symposiums during The Liver Week.

Second, fostering young researchers is crucial for the advancement of future medicine. I will provide more educational and research opportunities for young researchers in the Korean Association for the Study of the Liver. To maximize research funding, I will ensure meticulous financial management. Furthermore, I will refine various guidelines, STC, PG courses, and educational programs within The Liver Week to support the research, treatment, and education of young researchers.

Fourth, I will enhance the exchange among members for the academic and policy development of the association. Particularly, clinicians and basic researchers dedicated to regional healthcare face limitations in participating in society activities, multicenter research, and multinational clinical studies, hindering long-term development. Therefore, I will strive to promote nationwide research activities and provide opportunities for participation in various research projects. Collaboration with various pharmaceutical industries will also be strengthened in research and associative activities.

Finally, I will collaborate with the Korean Liver Foundation to advance clinical research methodology workshops and promote nationwide public relations events such as Liver Day. Additionally, I will proactively participate in national policies, aiming to provide substantial support for the clinical treatment and research conducted by the Korean Association for the Study of the Liver members.

Dear esteemed Members of the Korean Association for the Study of the Liver,

The associative conditions surrounding our association are becoming increasingly challenging, and we find ourselves facing new and unpredictable challenges. As the Chairman of the Board of the Korean Association for the Study of the Liver during this critical time, I feel a sense of unease. However, knowing that I am not alone but instead, I am with you, our esteemed members, I firmly believe that the new executive board, working together, will overcome any adversity and achieve remarkable development as demonstrated by the history of our association. I sincerely request your active participation and generous advice.

Thank you.